An overview of innovative cancer drug clinical development in China

Abstract

Abstract China starts to play more and more important role in the global arena of cancer drug development. From investigator’s perspective, this talk provides an overview of China cancer drug development, and strategy for future success. There are gaps between China and other countries in investment and length of drug development. With regulation reforms, cases show the drug development speed has been significantly improved. Large oncology patient population and unmet medical need make China an attractive market for cancer drug development. However, there is a big potential to be unleashed in early phase studies including phase I cancer trials in China. This talk also shares experience of how to build such an early clinical trial platform, with a professional clinical trial team, efficient management model and advanced technologies. Based on current situation, we need to discuss how to accelerate anticancer new drug research and develop more efficient and economic drugs for both China and Asian cancer patients.